Magic Mushrooms Meet Corporate Conspiracy: Steve Hely on Adult Swim’s Common Side Effects Post published:February 17, 2025 Post category:Interviews
mpathic Co-Founder Danielle Schlosser on AI Oversight of Psychedelics Trials Post published:January 17, 2025 Post category:Interviews/Pα+
Bullish on Chaos: Matt Zorn on How Psychedelics Could Benefit from Trump’s Second Term Post published:December 13, 2024 Post category:Interviews
Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field Post published:December 5, 2024 Post category:Interviews/Pα+
Exclusive: David Hough on Lykos’ Path to Resubmission Post published:September 4, 2024 Post category:Interviews/Pα+
Funding the Future of Psychedelic Medicine in Europe: An Interview with Norrsken Mind Post published:July 3, 2024 Post category:Interviews
In Conversation: Joanna Kempner, Author of “Psychedelic Outlaws: The Movement Revolutionizing Modern Medicine” Post published:June 18, 2024 Post category:Interviews
Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran Singh Post published:April 12, 2024 Post category:Interviews/Pα+
Senator Kirk Cullimore on Utah’s MDMA and Psilocybin Pilot Program Post published:April 3, 2024 Post category:Interviews
Fluence’s Elizabeth Nielson on Professional Education for the Psychedelics Field Post published:March 19, 2024 Post category:Interviews/Pα+